Cybin has announced key highlights from its study evaluating Kernel’s Flow wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
Awakn Life Sciences has announced that its Phase III clinical trial exploring the use of ketamine-assisted therapy for the treatment of severe alcohol use disorder (AUD)...
A team of researchers at the University of Pennsylvania School of Medicine have published findings which show how ketamine dramatically reorganises activity in the brain –...
Awakn Life Sciences has announced that it has signed a five-year lease to open Awakn Clinics Trondheim.
Irwin Naturals is branching into the psychedelics space with the aim of establishing the world’s largest chain of psychedelic mental health clinics.
Awakn Life Sciences has announced the signing of a five-year lease to open a larger Awakn Clinics Oslo.
Awakn has entered into a new partnership agreement with Nushama, one of New York’s leading ketamine-assisted therapy centres.
Awakn’s wholly-owned subsidiary, Awakn Oslo AS, has entered into a debt financing agreement with TD Veen AS, a family-owned, Norwegian investment company and current shareholder of...
HMNC Brain Health has raised €14.3m in a funding series, raised from existing investors, including Carsten Maschmeyer, the Jahr Group and Guntard Gutmann.
Awakn CEO, Anthony Tennyson, spoke to Psychedelic Health about the company’s plans to make ketamine therapy accessible to US patients.
